Jafron Biomedical Co., Ltd. (300529) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Jafron Biomedical Co., Ltd.

Why is Jafron Biomedical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -1.20% and Operating profit at -8.74% over the last 5 years

Flat results in Mar 26

OPERATING CASH FLOW(Y) Lowest at CNY 761.04 MM
NET SALES(9M) At CNY 1,438.03 MM has Grown at -16.85%

With ROE of 15.27%, it has a expensive valuation with a 2.32 Price to Book Value

Over the past year, while the stock has generated a return of -22.86%, its profits have fallen by -20.5%
At the current price, the company has a high dividend yield of 4.9

Below par performance in long term as well as near term

Along with generating -22.86% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Jafron Biomedical Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Jafron Biomedical Co., Ltd.

-34.4%

-1.62

24.42%

China Shanghai Composite

3.56%

1.20

14.07%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-1.20%

EBIT Growth (5y)

-8.74%

EBIT to Interest (avg)

25.28

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.33

Sales to Capital Employed (avg)

0.46

Tax Ratio

18.49%

Dividend Payout Ratio

75.36%

Pledged Shares

Institutional Holding

ROCE (avg)

35.37%

ROE (avg)

24.21%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.25

EV to EBIT

15.66

EV to EBITDA

13.63

EV to Capital Employed

4.60

EV to Sales

5.24

PEG Ratio

Dividend Yield

3.50%

ROCE (Latest)

29.38%

ROE (Latest)

15.27%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0.03% (YoY

NET PROFIT(9M)

Higher at CNY 468.24 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.65 times

OPERATING PROFIT MARGIN(Q)

Highest at 46 %

-5What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 645.22 MM

NET SALES(Q)

At CNY 471.85 MM has Fallen at -19.56%

Here's what is working for Jafron Biomedical Co., Ltd.

Operating Profit Margin

Highest at 46 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Inventory Turnover Ratio

Highest at 1.65 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Net Profit

Higher at CNY 468.24 MM

than preceding 12 month period ended Jun 2026

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (CNY MM)

Raw Material Cost

Fallen by 0.03% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at CNY 35.63 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (CNY MM)

Depreciation

At CNY 35.63 MM has Grown at inf%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (CNY MM)

Here's what is not working for Jafron Biomedical Co., Ltd.

Operating Cash Flow

Lowest at CNY 645.22 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Sales

At CNY 471.85 MM has Fallen at -19.56%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (CNY MM)